Amgen Inc. — 2020 Form 10-K Summary
Business context and reporting period. Amgen is a global biotechnology company operating in one segment, human therapeutics. This annual report covers the fiscal year ended December 31, 2020; quarterly figures below identify the three months ended December 31, 2020. Amounts are in U.S. dollars.
Financial performance
| Metric | FY 2020 | FY 2019 | Change |
|---|---|---|---|
| Total revenue | $25.424 billion | $23.362 billion | +9% |
| Product sales | $24.240 billion | $22.204 billion | +9% |
| Operating income | $9.139 billion | $9.674 billion | -6% |
| Net income | $7.264 billion | $7.842 billion | -7% |
| Diluted EPS | $12.31 | $12.88 | -4% |
| Operating margin | 35.9% | 41.4% | Down |
| Net margin | 28.6% | 33.6% | Down |
| Operating cash flow | $10.497 billion | $9.150 billion | +15% |
| Cash, cash equivalents and marketable securities | $10.647 billion | $8.911 billion | +$1.736 billion |
| Total debt | $32.986 billion | $29.903 billion | +$3.083 billion |
Cost of sales rose 41% to $6.159 billion, or 25.4% of product sales versus 19.6% in 2019; product-sales gross margin therefore declined to 74.6% from 80.4%. Management attributed the cost increase principally to Otezla acquisition-related amortization, higher royalties and profit sharing, partly offset by lower manufacturing costs. R&D expense was $4.207 billion (+2%); SG&A was $5.730 billion (+11%). Effective tax rate fell to 10.7% from 14.2%, contributing to lower net income but partly cushioning operating-income declines.
Fourth quarter: product sales were $6.334 billion, versus $5.881 billion in Q4 2019 (+8%); net income was $1.615 billion versus $1.703 billion, and diluted EPS was $2.76 versus $2.85. Gross profit from product sales was $4.737 billion versus $4.628 billion, implying a gross margin of approximately 74.8% versus 78.7%.
Current assets were $21.144 billion and current liabilities $11.653 billion at year-end (current ratio approximately 1.81). Cash from operations exceeded capital expenditures of $608 million. Financing cash flow included $8.914 billion in debt issuance proceeds, $6.450 billion in debt repayments, $3.755 billion in dividends and $3.486 billion in share repurchases. Amgen reported no material off-balance-sheet arrangements. The $2.5 billion revolving credit facility was undrawn, and the company reported compliance with debt covenants.
Material changes versus 2019
- Product sales increased, led in part by a full year of Otezla, acquired in November 2019. Otezla generated $2.195 billion in 2020 sales. Other growth contributors included Repatha (+34%), while Neulasta sales fell 29% amid biosimilar competition.
- Other notable product movements: ENBREL -4%, Prolia +3%, XGEVA -2%, Aranesp -9%, KYPROLIS +2%; total other product sales rose 19%.
- Despite revenue growth, operating income and net income declined as expenses increased. Total operating expenses rose 19%, particularly cost of sales and SG&A.
- Operating cash flow increased to $10.497 billion. Investing cash flow turned to a $5.401 billion outflow, primarily reflecting $3.219 billion of equity-method investment purchases, including BeiGene-related investment, and net marketable-securities outflows.
- Debt increased, while the current portion declined from $2.953 billion to $91 million, reflecting repayment and refinancing activity. The company issued approximately $9.0 billion of debt and repaid $6.5 billion during 2020.
Outlook, management commentary, risks and unusual items
- Management reported a moderate COVID-19 impact in 2020, with no material disruption to medicine supply reported. Patient access, diagnosis and clinical-trial enrollment were affected; demand recovered unevenly. Management expects continued sales volatility while the pandemic persists.
- No numeric 2021 revenue, earnings or EPS guidance is provided in the supplied filing text. Management expects net selling prices to continue declining, additional competition against biosimilars, and continued declines for ENBREL and Aranesp. Neulasta remains exposed to biosimilar pressure. 2021 capital-project spending was estimated at approximately $900 million.
- Pipeline developments included FDA approval of RIABNI in December 2020 (U.S. launch in January 2021), positive Phase 3 tezepelumab severe-asthma results, and sotorasib Breakthrough Therapy designation and regulatory submissions. The tezepelumab SOURCE trial for reducing oral corticosteroid dose missed its primary endpoint; management said this did not alter submission plans. Amgen ended its omecamtiv mecarbil collaboration and planned to transfer development and commercialization rights to Cytokinetics.
- Key business risks include biosimilar and generic competition, pricing and reimbursement pressure, payer and wholesaler concentration, patent disputes, clinical and regulatory uncertainty, manufacturing and supplier dependence, and COVID-related disruption. Three wholesalers represented 83% of worldwide gross revenues; the same three accounted for 74% of net trade receivables at year-end.
- Significant matters include IRS disputes concerning allocation of profits between U.S. entities and Puerto Rico for tax years 2010–2015; Amgen reported $3.352 billion of gross unrecognized tax benefits and $783 million of accrued related interest and penalties. The company elected to pay $5.575 billion of remaining U.S. repatriation tax in installments. Legal proceedings include disputes involving Aimovig collaboration rights, product patents, and antitrust claims; the filing states that potential loss ranges generally could not be estimated or were not material.
- Sales deductions were 44% of gross product sales in 2020, up from 41% in 2019; the accrued balance was $4.801 billion. Ernst & Young issued unqualified opinions on the financial statements and internal controls, and identified sales deductions and unrecognized tax benefits as critical audit matters.
Important facts for investors to verify
- Whether Otezla and newer products can sustain growth sufficient to offset falling prices and lost sales from biosimilar or generic competition.
- How 2021 product demand, net selling prices, patient access and clinical-trial activity develop as COVID-19 conditions change.
- The outcome and potential financial exposure of IRS transfer-pricing disputes, including the adequacy of tax accruals.
- Whether accrued sales deductions of $4.801 billion remain adequate as rebates, payer terms and product mix evolve.
- Debt maturities, refinancing costs and the sustainability of dividends and repurchases alongside planned investment and acquisitions.
- Regulatory and commercial prospects for sotorasib and tezepelumab, and the implications of tezepelumab’s missed SOURCE endpoint.